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ABSTRACT 
Synthetic cannabinoids were first created in a pharmaceutical setting where 
scientists were studying marijuana.  Researchers were trying to develop medically 
beneficial marijuana analogs.  The compounds, however, were found to give 
physiological effects that were more potent than marijuana.  Presently, synthetic 
cannabinoids have become a psychoactive drug of abuse, sold in head shops and over the 
Internet.  New compounds are constantly being synthesized, which makes analysis of the 
drugs difficult.   
Solid phase extraction (SPE) is a well-studied method used in toxicological 
analysis to extract drugs and their metabolites from biological fluids.  This sample 
preparation method is necessary to isolate the desired components of a sample for 
analysis by gas chromatography and mass spectrometry (GC/MS).  This study sought to 
compare four brands of commercially available SPE cartridges using a procedure from 
United Chemical Technologies (UCT) for the simultaneous extraction of the three 
synthetic cannabinoid metabolites, JWH-018 N-(4-hydroxypentyl), JWH-122 N-(5-
hydroxypentyl), and JWH-250 N-(5-hydroxypentyl), from urine.  The cartridges from 
UCT, Thermo Scientific, Agilent Technologies, and SiliCycle were evaluated to 
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determine how they performed throughout the SPE procedure.  A recovery efficiency 
study was conducted to measure the amount of extracted metabolites from the urine.  The 
responses of the quantification ion of the metabolites from an extracted urine sample 
were compared to a neat sample and the percent recovery was calculated.  A within-run 
precision study was also utilized to measure the reproducibility of the cartridges, which 
was determined by the coefficient of variation (CV) of the different brands. 
The outcome of this research led to a development of a GC/MS method for 
detection of the three metabolites, creation of calibration curves for quantification, use of 
SPE for the extraction of the metabolites from urine, and the quantification of the 
extracted compounds to determine the efficacy and consistency of four brands of SPE 
cartridges.   Method optimization was able to minimize the interday variations seen in the 
results of aliquots of the same samples.  Optimal parameters include initial validation of 
the GC/MS method, a clean liner for the analysis of synthetic cannabinoid metabolites, 
using a GC column with a high temperature limit, and derivatization of the extracts 
before injection into the GC.  While this study shows it is possible to use GC/MS for the 
analysis of these metabolites, LC/MS does not have the same restrictions because a liner, 
temperature elution, and derivatization of the analytes are not utilized.   
It was determined from the results of these studies that SiliCycle had the most 
reproducible and efficient cartridges.  SiliCycle cartridges had a consistent and fast flow 
rate with a percent recovery efficiency within ±20% of the actual value.  The results from 
SiliCycle were followed by cartridges from UCT, Thermo Scientific, and Agilent brands, 
respectively. 
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1. INTRODUCTION 
1.1 Synthetic Cannabinoids 
1.1.1 Research History 
Synthetic cannabinoids are psychoactive drugs of abuse, originally studied in 
pharmaceutical laboratories beginning in the 1960’s.  The research scientists in these labs 
were trying to develop medically useful derivatives of delta9-tetrahydrocannabinol (Δ9-
THC) that contained its analgesic and anti-inflammatory benefits, without the 
psychoactive effects (1, 2).  With the discovery of the cannabinoid receptors type 1 (CB1) 
and type 2 (CB2), which are for endogenous neurotransmitters such as anandamide, it 
was determined that the compounds being developed were agonists to those receptors 
with a higher binding affinity than Δ9-THC  (2-11).  This resulted in more potent 
compounds that were not medically useful at the time.  The CB2 receptor, located in the 
peripheral nervous system, involves pain perception in which many therapeutic benefits 
could be developed, like reducing nausea and intraocular pressure (9, 12-14).  The CB1 
receptor, located in the central nervous system, includes the psychoactive effects, such as 
visual and auditory hallucinations (9, 12-14). 
Among the first synthetic analogs were the enantiomeric cannabinoid compounds 
HU-210 and HU-211, which were synthesized in Raphael Mechoulam’s laboratory at the 
Hebrew University (HU) of Jerusalem, and CP-47,497 which was synthesized by Pfizer 
in the 1980’s (15, 16).  Alexandros Makriyannis (AM) at Northeastern University and 
John W. Huffman (JWH) at Clemson University also contributed to the research of 
synthetic analogues of cannabinoids.  Huffman designed many cannabimimetic indoles in 
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the early 1990’s by replacing the aminoalkyl’s with n-alkyl chains (9, 17).  Specifically, 
his research allowed for the design of hundreds of JWH compounds, which were among 
the first synthetic cannabinoids found in herbal incense blends being used as recreational 
drugs (17).  Using Howlett’s et al. classification system in Pharmacological Reviews, the 
different structures of synthetic cannabinoids can be separated into four categories: 
classical cannabinoids, nonclassical cannabinoids, aminoalkylindoles, and eicosanoids 
(9).  The structures of these compounds can be seen in Figure 1. 
 
 
Figure 1.  Structures of various synthetic cannabinoids. Classical cannabinoids A.) 
Δ9-THC and B.) HU-210; Nonclassical cannabinoid C.) CP-47,497; Aminoalkylindole 
D.) JWH-018; Eicosanoid E.) anandamide. 
 
 
1.1.2 Use and Health Effects of Synthetic Cannabinoids 
Herbal marijuana alternatives, smart drugs, and legal highs are all names given to 
these new psychoactive compounds.  The abuse of these drugs is part of a trend to 
provide consumers with substances advertised as natural, herbal products that give a 
A.! B.!
C.! D.! E.!
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marijuana-like high, without its legal ramifications (1, 2, 4, 15).  While some of the plant 
material contains psychoactive properties of their own, like leonurine or nuciferine, the 
synthetic cannabinoids are sprayed on dried plant material and sold over the Internet 
disguised as incense (1, 4).  These substances are advertised as a legal substitute for 
marijuana and sold under different brand names, including Tropical Synergy, Spice, K2, 
and Kronic.  After the popularity of these drugs increased, the manufacturers began using 
cheaper plant materials to gross a higher profit (18). 
Synthetic cannabinoids produce similar effects to marijuana, such as euphoria, 
relaxation, and perception alterations, but due to their increased binding affinities, the 
effects can be much more intense (3, 19).  The adverse side effects of these compounds 
include anxiety, paranoia, delusions, agitation, and high blood pressure (1, 19, 20).  
Withdrawal symptoms have been discovered in several accounts of prolonged synthetic 
cannabinoid use, including tremors, insomnia, diarrhea, headaches, and depression (2).  
Research has also shown cannabis use can increase the risk of psychosis in individuals 
with a personal or familial history of mental illness, and the risk can be even more 
prevalent because of the increased binding affinity of synthetic cannabinoids (21-23).  
One case report involves a man with a history of cannabis induced psychotic episodes 
being reactivated after using synthetic cannabinoids (24). 
Abuse of synthetic cannabinoids began in Europe in the early 2000’s, and it 
spread to Japan, the United States (U.S.), and Australia throughout the following decade 
(1, 3, 25, 26).  In 2008, the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) began to ascertain what was referred to as “Spice” was not herbal, and 
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German scientists discovered that these new compounds were not detected by drug 
screens (2, 18).  This inconspicuous quality makes synthetic cannabinoids very appealing 
to a variety of people.  They are also easily accessible with cannabis-like effects, and are 
advertised to be natural and safe.  The rapid onset and shorter duration of the compounds 
are also enticing to users (2-4, 19, 22, 27).  According to an anonymous online survey, in 
2011, 17% of the almost 15,000 participants worldwide reported trying synthetic 
cannabinoids (27).  These individuals cited several of the previous reasons for their 
explanation of use (27).  Approximately 93% of these users preferred natural cannabis, 
stating there were more negative effects and longer hangovers associated with their 
synthetic variants (27).  
While these synthetic compounds have similar physiological effects to marijuana, 
immunoassay screening techniques such as kinetic interaction of microparticles in a 
solution and enzyme multiplied immunoassay technique do not demonstrate cross 
reactivity for the compounds (1, 20).  With the wide variety of synthetic derivatives 
constantly changing, the selectivity of a target analyte is hard to identify and then utilize 
for screening (15).  Developing a technique for one subcategory of compounds may not 
work on others due to the differences in the chemical structures.  The availability of the 
parent drugs and metabolites, limited knowledge of the newer compounds, and a limited 
spectral library require continuous research to be conducted on these new drugs (15, 28). 
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1.1.3 Legality and Risks of Synthetic Cannabinoid Use 
Synthetic cannabinoids are continuously changing, making the compounds 
difficult to legislate.  Banning began as early as 2008 in Germany, with other European 
countries, Russia, Australia, and New Zealand following suit in 2010 and 2011 (1, 4, 7, 8, 
27).  In the U.S., temporary placement of five synthetic cannabinoid compounds as 
schedule I began in 2010 (29).  An extension was placed on the scheduling until Congress 
passed the Synthetic Drug Abuse Prevention Act (SDAPA) in 2012 (30, 31).  This 
addition to the Controlled Substances Act states that all cannabimimetic agents, including 
any compound that is a CB1 agonist, are schedule I (31).  In the U.S., exposure to 
synthetic marijuana peaked in 2011 when the American Association of Poison Control 
Centers logged almost 7,000 reports (32).  This number has significantly dropped in the 
following years as the legislation has taken effect  (32).  The World Anti-Doping Agency 
also added natural and synthetic Δ9-THC, as well as cannabimimetics to their 2013 
prohibited substances list (33).  Regulation was difficult due to the rapid production of 
new compounds once one was banned or scheduled.  However, with the specification of 
any cannabimimetic agents being classified as schedule I in the SDAPA, progress has 
been made to control these substances.  
Constant synthetic modifications to these compounds can lead to health risks for 
consumers because the metabolism and toxicology of the synthesized cannabinoids 
remain unknown (34).  Serious side effects or possible drug overdose could result from 
the changes between batches and the unknown toxicity of these synthetic cannabinoids.  
A German study, conducted in 2008-2009, demonstrates how quickly the banning of 
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various compounds affects the modifications of the synthetic cannabinoids used as herbal 
marijuana alternatives (4).  Before JWH-018 and CP-47,497-C8 were banned, they were 
detected in 69% of the samples tested, which decreased to 28% after the banning 
occurred (4).  This led to an increase in JWH-073 being detected, as well as multiple 
samples containing no synthetic cannabinoids, but including substances like harmine, 
harmaline, caffeine, nicotine, Δ9-THC, and cannabidiol (4).  Their study helps to 
visualize the quick turnaround for these drugs of abuse since a new compound 
immediately replaces the banned compound. 
 
1.2 Synthetic Cannabinoid Metabolites 
1.2.1 Metabolism of Synthetic Cannabinoids 
The human body metabolizes drugs in order to excrete them from the body.  One 
way to accomplish this is by aliphatic hydroxylation, in which cytochrome P450 adds a 
hydroxyl group to the carbon chain to make the compound more polar (35).  Figure 2 
shows the aliphatic hydroxylation of a JWH compound.  In the analysis of urine samples, 
the metabolites of the synthetic cannabinoids are more prevalent than the parent 
compounds, which may not be seen at all (1, 7, 12, 14, 34, 36-38).  Due to these results, 
the sample preparation and analysis must be optimized for the metabolites themselves.  
The synthetic cannabinoids exist in various forms with their own metabolites, all of 
which have different properties and react with the methods of analysis in diverse ways.  
This variety is why synthetic cannabinoids are difficult to analyze.  Compounds are not 
always identified because extensive libraries do not exist. 
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Figure 2: Aliphatic hydroxylation.  Synthetic cannabinoid JWH-018 metabolized to 
JWH-018 N-(4-hydroxypentyl).   
 
 
1.2.2 Metabolites Utilized in this Study 
Three synthetic cannabinoid metabolites were selected to use in this study.  
Compounds JWH-018 N-(4-hydroxypentyl), JWH-122 N-(5-hydroxypentyl), and JWH-
250 N-(5-hydroxypentyl) metabolites were chosen for their availability and appearances 
in scientific literature.  The JWH-018 compound was first identified in smoking mixtures 
in Germany and Austria in 2008, with JWH-250 identified in 2009, and JWH-122 in 
2010 (7, 10, 38).  The monohydroxylated forms of the metabolites, with the hydroxyl 
group on the aliphatic chain, were found to be the most common in urinalysis (7, 38).  
For these reasons, these metabolites with their deuterated internal standards seen in Table 
1, were chosen for this study.  
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Table 1.  Structures of the metabolites and  
deuterated internal standards utilized in this study. 
Synthetic 
Cannabinoid Structure d5 Internal Standard 
JWH-018 
N-(4-hydroxypentyl) 
 
MW: 357 
 
MW: 362 
JWH-122 
N-(5-hydroxypentyl) 
 
MW: 371 
 
MW: 376 
JWH-250 
N-(5-hydroxypentyl) 
 
MW: 351 
 
MW: 356 
 
 
1.2.3 Current Methods of Analysis for Synthetic Cannabinoids and Metabolites 
There have been multiple studies done testing methods of analysis on specific 
parent compounds and metabolites, including several JWH compounds  (7, 8, 10, 37, 38).  
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These studies are typically conducted individually, showing the difficulty in creating a 
unified method of analysis for all synthetic cannabinoids and their metabolites.  With the 
limited availability of the compounds, research conducted on the variety of synthetic 
cannabinoids and their metabolites has been difficult.  Early research in the analysis of 
the metabolites required the researchers to synthesize the metabolites themselves (36).  In 
vitro studies using human liver microsomes and in vivo studies using chimeric mice to 
create the metabolites were performed so analysis of the metabolites could be conducted 
(12, 14).  Companies are now beginning to synthesize the parent compounds and their 
metabolites at a faster rate, allowing more research to be conducted.  However, the recent 
scheduling recommended by the SDAPA in 2012 hinders research because schedule I 
licenses are now required to study these compounds.  
Methods of analysis for synthetic cannabinoids vary greatly depending on the 
compounds, whether the metabolites are involved, and the matrix of the sample.  Solid 
phase extraction (SPE) and liquid-liquid extraction (LLE) are used in sample preparation 
of the synthetic cannabinoid metabolites.  Gas chromatography (GC) and liquid 
chromatography (LC) are used for separation, coupled with mass spectrometry (MS) for 
detection.  Synthetic cannabinoids have been detected on plant material from herbal 
incense samples purchased online using GC/MS for analysis (20, 26).  Methods using 
GC/MS and LC/MS have been validated to identify synthetic cannabinoids from different 
matrices like blood, hair, and oral fluid (3, 28, 39, 40).  Research studies have been 
performed comparing solvent extraction and SPE to isolate the metabolites from urine, of 
which little difference was found (7, 38).  Extracted urine samples for synthetic 
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cannabinoid metabolites have been studied by different forms of both LC/MS and 
GC/MS.  The two methods of analysis have been compared, with LC being able to 
identify more of the minor metabolites (7, 37).   
One study conducted by Dowling and Regan performed a quick method of 
analysis in which the researchers spiked urine with CP-47,497 and utilized LC-MS/MS 
for the analysis by diluting the samples with water and acetonitrile without extraction (6).  
The removal of a sample preparation step before analysis is beneficial, allowing time and 
money to be saved.  
Restek performed a study on extraction efficiency of JWH-018 and -073 
metabolites using a C18 SPE cartridge, with analysis by LC-MS/MS (41).  They were 
able to develop a procedure to extract a wide range of metabolites from the samples, 
including monohydroxylated and carboxylated metabolites (41).  This experiment is 
significant because the range of metabolites produced by the body interact with the 
sorbent of the cartridges differently.  The carboxylated and hydroxylated metabolites are 
usually extracted separately due to their differences in pKa values.  A procedure that can 
only isolate one type of metabolite is not as useful in a real life setting, since the drugs of 
abuse can be mixtures of many compounds.     
 
1.3 Solid Phase Extraction 
SPE is a sample preparation method that isolates the analytes of interest from 
biological matrices (35).  This is achieved via a sorbent that interacts with the analyte.  
Solvents are eluted through the cartridge to remove extraneous components according to 
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the affinity of the compounds with the sorbent (35).  The interactions can be manipulated 
using solubility, adsorption, binding, or electrostatic interactions between the sorbent and 
analyte.  SPE has multiple benefits over LLE, which uses a larger volume of solvents to 
separate compounds, has limited quantitative recoveries because it may require a three-
step extraction procedure, and may undergo incomplete phase separations (35).  SPE also 
minimizes the amount of liquid organic waste and can be automated (35).   
The process of SPE includes four main steps: conditioning the cartridge to prepare 
the sorbent and pack it evenly, applying the sample for the analyte to interact with the 
sorbent, washing the column to remove the unwanted components, and eluting the 
analytes with different solvents.  Extraction efficiency is not 100% because the analytes 
interact with the sorbent to varying degrees.  The analytes could have a weak interaction 
with the sorbent and be eluted before the elution step, or they could have a strong 
interaction and stay adsorbed to the sorbent after elution.  For a more efficient extraction, 
the method development, solvents utilized, and choice of sorbent are critical for the 
sample preparation.   
 
1.4 Derivatization 
While GC is an appropriate separation method for many substances, it has 
specific requirements.  The compounds must be volatile because they are vaporized in the 
injection port and enter the column as a gas.  The high injection port temperatures needed 
for vaporization also require that the compounds be thermally stable so they do not 
decompose before reaching the column (42).  The last consideration for GC is the 
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polarity of the compounds.  Polar groups can interact with a polar column, causing the 
analytes to elute broadly, resulting in poor peak shape (42).  To alleviate these issues, 
derivatization is utilized.  This procedure modifies the compounds to increase thermal 
stability and volatility, and decrease polarity (43).  
Since the body metabolizes synthetic cannabinoids by making them more polar, a 
derivatizing agent is highly recommended when analyzing toxicological samples by 
GC/MS.  N,O-bis(trimethylsilyl) trifluoroacetamide (BSTFA) is a silylating reagent that 
replaces the labile hydrogen of the hydroxyl with a trimethylsilyl group, increasing 
volatility and thermal stability (42).  Trimethylchlorosilane (TMCS) is a catalyst that 
helps to increase the reactivity of BSTFA (43).  The derivatized metabolites used in these 
experiments can be seen in Table 2.  
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Table 2.  Structures of the metabolites and derivatized metabolites utilized in this study. 
Synthetic 
Cannabinoid Structure Derivatized Metabolite 
JWH-018 
N-(4-hydroxypentyl) 
 
MW: 357 
 
MW: 429 
JWH-122 
N-(5-hydroxypentyl) 
 
MW: 371 
 
MW: 443 
JWH-250 
N-(5-hydroxypentyl) 
 
MW: 351 
 
MW: 423 
 
 
1.5 Objective of this Research 
The purpose of this research was to compare the reproducibility and efficacy of 
four brands of SPE cartridges for the simultaneous extraction of the three JWH 
metabolites from urine.  In order to accomplish this, the instrumental and data analysis 
methods were optimized for these specific metabolites and their internal standards.  An 
appropriate GC/MS method was selected and optimized for analysis of the compounds.  
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Next, a SPE procedure from United Chemical Technologies (UCT) for the extraction of 
“Spice” from urine was utilized to isolate the metabolites (44).  Triplicate samples of 
three concentrations were compared for each cartridge.  A multi-point calibration method 
was created to quantify the metabolites after the extraction from urine. 
Since these synthetic cannabinoids have a higher affinity than Δ9-THC to the 
cannabinoid receptors, a lower dose is needed to obtain the same high.  This results in a 
lower concentration located in body fluids, so a change in the reproducibility of the 
cartridges could be very important.  If one cartridge is better suited for lower 
concentrations, it should be utilized above a cartridge that produces no results.  
Numerous brands of cartridges and SPE methods were researched in order to determine 
the best sorbent and procedure to utilize for these analytes.  The same SPE procedure was 
conducted on all of the samples and observations were made to determine the consistency 
of the elution flow rate through the cartridges.  These experiments allowed for a 
comparison of the cartridges, with the most appropriate brand to be determined. 
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2. EXPERIMENTAL 
2.1 Materials 
The metabolites and deuterated internal standards of (±)-JWH-018 N-(4-
hydroxypentyl), JWH-122 N-(5-hydroxypentyl), JWH-250 N-(5-hydroxypentyl), (±)-
JWH-018 N-(4-hydroxypentyl)-d5, JWH-122 N-(5-hydroxypentyl)-d5, and JWH-250 N-
(5-hydroxypentyl)-d5 were obtained from Cayman Chemical.  The chemicals purchased 
from Fisher Scientific include methanol (MeOH), deionized water (diH2O), ethyl acetate 
(EtOAc), and acetonitrile (ACN).  Anhydrous mono- and di-basic sodium phosphates, 
NaH2PO4 and Na2HPO4, were obtained from Acros Organics.  Synthetic urine and 
BSTFA with 1% TMCS were obtained from Cerilliant.  The nitrogen gas was purchased 
from Airgas East.  A TurboVap LV Evaporator from Zymark and an Isotemp 2025 hot 
water bath from Fisher Scientific were used for solvent evaporation and derivatization.  
The four, reverse phase, anion exchange solid phase extraction cartridges were purchased 
from Agilent Technologies, United Chemical Technologies (UCT), Thermo Scientific, 
and SiliCycle.  Specifics about the cartridges names can be seen in Table 3.   
Table 3.  SPE cartridges compared in these experiments. 
Vendor Cartridge Name 
UCT Clean Screen Extraction  Columns CSTHC 
SiliCycle Siliaprep C8/SAX 
Agilent Bond Elut Certify II 
Thermo HyperSep Verify AX 
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An Agilent 7890A GC combined with an Agilent 5975C inert EI/CI MSD was 
equipped with an Rxi®-5ms (30 m x 0.25 mm x 0.25 μm) column from Restek with a 
temperature limit of 350oC.  As a result of the nature of the compounds and the GC/MS 
parameters requiring a higher injection port temperature, the column was changed to an 
Rxi®-5ht (30 m x 0.25 mm x 0.25 μm) column from Restek with a higher temperature 
limit of 400oC.  Data analysis was conducted using MSD ChemStation E.02.00.493 
software from Agilent.  GC vials, liners, and caps were obtained from Fisher Scientific. 
 
2.2 GC/MS Method Development 
A stock solution of each metabolite was prepared in methanol at a concentration 
of 1 mg/mL.  A working solution containing all metabolites in methanol at a 
concentration of 50 μg/mL as well as a working solution of the internal standards in 
methanol at 5 μg/mL were prepared for the GC/MS method development.  Mixtures of 
the three metabolites in a 1:1:1 ratio were added to methanol and six GC/MS methods 
were tested.  A method from Agilent Technologies for the “Confirmation and 
Quantification of Synthetic Cannabinoids” resulted in the best resolution between peaks, 
had the fastest run time, and increased sensitivity for the detection of these metabolites 
(45).  This method was selected and changes were made for the specific metabolites.  
Interday analysis by GC/MS fluctuated greatly.  Therefore, multiple parameters of the 
method were tested in order to reduce the variation.  The injection temperature, injection 
volume, inlet mode, pressure and total flow, oven program, carrier gas flow rate, transfer 
line temperature, and solvent delay were optimized for the metabolites.  A new GC liner 
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set aside for these experiments was used every time the metabolites were injected into the 
instrument because it was found to produce more reproducible chromatograms in 
comparison to a liner used for other samples.   
For quantification of the analytes, a multi-point calibration method was created 
with the ChemStation software, using the optimized GC/MS method.  Seven calibration 
standards of the three metabolites from 30 ng/mL to 10 μg/mL with a deuterated internal 
standard concentration of 500 ng/mL were diluted and used to make the calibration 
curves.   
The results from the neat compounds were not consistent throughout early 
analysis conducted on the metabolites.  To combat the interday fluctuations of the 
instrumental analysis, derivatization of the metabolites was performed using BSTFA with 
1% TMCS.  A new set of six calibration standards from 5 ng/mL to 10 μg/mL of the 
metabolites and 300 ng/mL of the internal standards were evaporated to dryness, 
reconstituted in 50 μL BSTFA with 1% TMCS, and immersed in a 65oC water bath for 35 
minutes.  The previous GC/MS method was optimized for these derivatized compounds 
by testing parameters focusing on the oven program, injection temperature, and transfer 
line temperature.  The parameters for the final GC/MS method are shown in Table 4. 
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Table 4.  GC/MS parameters for analysis of the derivatized metabolites. 
Parameter  
Inlet Mode Split-less 
Injection 
Temperature 300
oC 
Injection Volume 2 μL 
Carrier Gas Constant flow, 0.9 mL/min 
Oven Program 
100oC for 1 min, then 25oC/min to 300oC 
for  
0.5 min, then 5oC/min to 325oC for 3 min 
Transfer Line 
Temperature 280
oC 
Solvent Delay 5 min 
Total Run Time 17.5 min 
 
 A SIM method for the metabolites and internal standards was created to increase 
sensitivity for the detection of these metabolites.  A dwell time of 50 milliseconds was 
utilized.  The literature recommends three high mass ions for the analyte and two for the 
internal standard to be used for quantification (46).  The SIM method assesses the 
selected quantifying and qualifying ions of the metabolites and internal standards in order 
to reduce the baseline of the chromatographic separation (35).  Utilizing two ions allowed 
the internal standard to be measured by a ratio, instead of the appearance of one ion.  The 
ions chosen for the metabolites and their internal standards are shown in Table 5.   
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Table 5.  Ions selected for SIM method. 
Metabolite Group Ions 
Group 1 
(JWH-250) 
MTB: 144, 302*, 423 
ISTD: 307*, 308 
Group 2 
(JWH-018) 
MTB: 270*, 296, 414 
ISTD: 418, 433* 
Group 3 
(JWH-122) 
MTB: 298, 428, 443* 
ISTD: 433, 448* 
Metabolite (MTB) and internal standard (ISTD) ions. 
*Starred ions indicate quantifying ions. 
 
2.3 Solid Phase Extraction Procedure 
UCT developed a SPE procedure for the extraction of synthetic cannabinoids 
from urine, which was used in these experiments (44).  Sample preparation started with 1 
mL of synthetic urine that was spiked with the metabolites and internal standard.  The 
urine was diluted with 2 mL of the pH 6 phosphate buffer solution.  The SPE procedure 
was conducted by gravity elution and the steps can be seen in Figure 3.  To concentrate 
the metabolites, the 6 mL of the 90:10 ethyl acetate and methanol solution was 
evaporated to dryness.  An evaporator was used to emit a constant stream of nitrogen gas 
over the solution, while the tubes were placed in heated water.  The samples were 
reconstituted in 50 μL of BSTFA with 1% TMCS, capped, and immersed in a 65oC water 
bath for 35 minutes.  The heat helped to catalyze the derivatization process.  The samples 
were then injected into the GC/MS for instrumental analysis. 
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Figure 3: Visualization of the SPE procedure.  The SPE cartridges were conditioned 
with 3 mL methanol followed by 3 mL diH2O and 1 mL buffer solution.  The sample of 3 
mL spiked urine was applied to the cartridge and then washed with 3 mL diH2O and 3 
mL of the 80:20 buffer and acetonitrile solution.  The cartridges were dried under 
vacuum for 5 minutes at >10 in mercury.  The metabolites were eluted with 6 mL of the 
90:10 ethyl acetate and methanol solution into clean vials. 
 
 
2.4 Data Collection 
Working solutions of the metabolite mixture were created in methanol at 10, 1, 
and 0.05 μg/mL concentrations.  A working solution of the deuterated internal standard 
mixture was created in methanol at a 1 μg/mL concentration.  Four sets of calibration 
standards were spiked into urine samples between 50 and 2000 ng/mL of the metabolites 
Condition 
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and 300 ng/mL of the internal standards.  The urine samples were used to create 
calibration curves for each of the four brands of cartridges. 
The metabolites were spiked into synthetic urine at three concentrations, 1000, 
500, and 250 ng/mL, with 300 ng/mL of the deuterated internal standards.  The SPE 
procedure was performed on the spiked samples in triplicate analysis for each of the four 
brands.  Blank synthetic urine samples were also processed using the SPE procedure in 
triplicate analysis. 
 
2.5 Data Analysis 
Multiple calibration curves for the synthetic cannabinoid metabolites spiked in 
methanol were created to determine the linear dynamic range of the GC/MS method.  A 
multi-point calibration method for the quantification of the neat standards was made 
using ChemStation software.  Calibration standards were prepared and the response ratio 
of the metabolite to the internal standard was plotted against the concentration ratio of the 
metabolite to the internal standard.  A least-squares line was applied and the coefficient 
of determination was used to determine the linearity of the curve.  Calibration curves 
were also created using the extracted spiked urine samples.  They were made for each 
metabolite and brand of cartridges compared in this research.  The methods were used for 
the quantification of the metabolites in the spiked samples. 
A recovery efficiency study was performed using the metabolite responses of the 
quantification ions.  The ratio of extracted metabolite responses from the cartridges to the 
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metabolite responses from neat, un-extracted samples spiked with the same 
concentrations was determined and a percent recovery was calculated from this ratio.   
One study from the Scientific Working Group for Forensic Toxicology 
(SWGTOX) was also used to analyze the collected data.  A within-run precision study 
measured the coefficient of variation for the triplicate samples of each cartridge brand 
using the standard deviation and mean response of the replicates (47): 
%  𝐶𝑉 =    𝑠𝑚𝑒𝑎𝑛  𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒   ∗ 100 
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3. RESULTS AND DISCUSSION 
3.1 GC/MS Concerns During Development of the Method 
3.1.1 GC/MS Method Optimization 
The GC/MS parameters from Agilent Technologies were found to be the most 
efficient for the detection of the three metabolites with the shortest run time, best 
resolution, and highest abundance for each metabolite.  During method optimization, 
several parameters were tested in order to create a method that produced consistent 
results.  A GC column with a temperature limit of 350oC was used during GC/MS 
method development.  Column degradation occurred due to the high temperatures above 
300oC for the injection port and oven parameters in the GC method.  The number of 
samples analyzed also affected the degree of degradation to the column.  This created 
abundant siloxane peaks in the chromatograms at the lower oven temperatures, as well as 
an increased baseline from a constant elution of siloxanes at the higher temperatures.  To 
decrease the damage, a column with a higher temperature limit of 400oC was utilized for 
the experiments conducted after the initial GC/MS method development phase.   
Interday analysis of the neat standards showed a great deal of variation in the peak 
area and ratio of the metabolites to each other.  An overlay of chromatograms of aliquots 
of the same sample injected on different days for three months can be seen in Figure 4.  
Observed in this figure are the peak heights of JWH-250 decreasing more significantly 
than the peaks of JWH-122.  This indicates that the interday variation affects each 
metabolite differently. 
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Figure 4: Chromatograms of the interday peak abundance variation of the 
metabolites.  Analysis of the three underivatized metabolites neat in methanol was 
conducted separately over three months to show the significant differences in peak area 
using the same method.  The ratios of the peak heights between the different metabolites 
were also affected.  Due to the abundance of the metabolites increasing between months 
1 and 2, it was determined that the variation was not due to the degradation of the 
metabolites in methanol. 
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3.1.2 JWH-018 Internal Standard  
The three internal standards in these experiments were chosen because they were 
the deuterated analogues of the three metabolites.  The internal standards are heavier than 
the metabolites, replacing five hydrogen atoms with deuterium.  The deuterated 
compounds improved the precision of the method because the metabolites and internal 
standards interact with the column in the same way (35).  During GC separation, the 
compounds have similar retention times, but due to the mass difference, analysis by MS 
identified them.  Each internal standard was a d5 version of the metabolite; therefore, the 
molecular ions of the internal standards were expected to be 5 atomic mass units (amu) 
greater than the metabolites.  However, the JWH-018 internal standard had a molecular 
ion that was only 4 amu higher than the JWH-018 metabolite.  The mass spectrum of the 
JWH-018 internal standard can be seen in Figure 5. 
 
Figure 5: Mass spectrum of JWH-018 deuterated internal standard.  The molecular 
ion is only 4 amu greater than the molecular ion of JWH-018 metabolite of 357 amu. 
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To determine whether this was a fragmentation effect from the hard ionization 
method of electron impact, a sample was analyzed by electrospray ionization (ESI) LC 
time of flight MS at Northeastern University.  ESI is a softer method of ionization that 
results in the protonated molecular ion (M+H)+, so the molecular ion observed is 1 amu 
higher than the molecular weight of the compound.   
The molecular ion by ESI-LC-TOF-MS was 362 amu.  Including the addition of 
the hydrogen, the results were in agreement with the molecular ion observed by electron 
impact ionization, which was 361 amu.  This indicated the ionization method did not 
cause the fragmentation.  The mass spectrum of the JWH-018 internal standard from the 
softer ionization method of ESI can be seen in Figure 6.  Even with derivatization, the 
molecular ion for the JWH-018 internal standard was 433 amu, which was 4 amu higher 
than the derivatized JWH-018 metabolite of 429 amu.  Since the results were consistent 
throughout the experiments, the internal standard was still utilized.  
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Figure 6: Mass spectrum of JWH-018 deuterated internal standard from 
electrospray ionization.  The spectrum shows the (M+H)+ ion at 362.  The 384 peak is 
from the addition of sodium (M+Na)+ to the compound.  The inset is a close up of the 
(M+H)+ peak.  
 
3.1.3 GC/MS Injection Liner Considerations 
Initial tests running neat standards in methanol produced the three metabolite 
peaks and three additional peaks eluting approximately 0.3-0.6 minutes before their 
respective metabolites, which is observed in Figure 7.  These additional peaks contained 
(M+H+) 
(M+Na+) 
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molecular ions that were 2 amu less than the metabolite and deuterated internal standard 
peaks they preceded, indicating a loss of two hydrogen atoms.  The degradation peaks 
retained similar fragmentation patterns to the metabolites, of which JWH-018 is shown in 
Figures 8 and 9.   
 
Figure 7: Chromatogram of the degradation observed from the analysis of JWH-
250, JWH-018, and JWH-122 metabolites.  The peaks observed to the left with a lower 
retention time are 2 amu less than the metabolites they precede.  This chromatogram 
demonstrates the most extreme degradation seen during this experiment.  
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Figure 8: Mass spectrum of JWH-018 metabolite. 
 
 
Figure 9: Mass spectrum of peak preceding JWH-018 metabolite. 
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becoming a ketone in the JWH-018 metabolite and an aldehyde in both JWH-122 and 
JWH-250 metabolites.  To determine whether the oxidation was caused by degradation of 
the samples, aliquots of the same mixture concentration were tested on different days 
after being stored for different periods of time.  There was no correlation between storage 
of the standards and peak area of the degraded standards.  However, a trend was 
discovered in the logbook between the instrument maintenance, number of samples 
injected, and when the metabolites were tested.  This information led to the determination 
that the GC liner affected the analysis of the metabolites.  The degraded metabolite peaks 
persisted until the GC liner was changed.   
Table 6 shows the percentage of peak area between the degraded peaks and their 
corresponding metabolite peaks.  The sample in the first trial was the result of a visibly 
dirty liner. Instrument maintenance which involved changing the liner, septum, and o-
ring, and cleaning the ion source was performed on the GC/MS between trials two and 
three, suggesting a possible solution to the problem, and significantly decreasing the 
degradation peaks from the JWH-250 and JWH-122 metabolites. 
Table 6.  Percentage of the degraded peak area to the metabolite peak area. 
Trial JWH-250 JWH-018 JWH-122 
1* 50.6% 72.7% 76.6% 
2 12.1% 17.6% 19.4% 
3 -- 19.6% -- 
4 -- 13.4% -- 
*Trial 1 is the chromatogram seen in Figure 6.  The dashes represent no percentage differences 
between the metabolite and degraded peak areas. 
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Due to the heavy use of the instrument analyzing a wide variety of samples, it was 
hypothesized that the build up of impurities in the liner caused the oxidation of the 
metabolites.  By using a new liner, there were no impurities to react with the metabolites.  
An aliquot of a 100 μg/mL mixture of the metabolites was injected using an older, visibly 
dirty liner and immediately injected again after the liner had been changed.  The 
chromatogram showing the increased sensitivity and decreased area of the oxidized peaks 
can be seen in Figure 10.  This significant increase in sensitivity allowed for the analysis 
of smaller concentrations of the standards in the rest of this research 
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Figure 10: Chromatograms of the metabolites with an old versus a new liner.  The 
overlay of the old liner in blue and new liner in red shows the significant increase in peak 
area of the metabolites and decrease of the three preceding peaks. 
 
While there was a significant amount of interday variability, samples analyzed on 
the same day had comparable results.  Calibration curves of the neat metabolites spiked 
in methanol were created.  The seven calibration standards were spiked with 30 ng/mL to 
10 μg/mL of the metabolites and 500 ng/mL of the internal standards.  The coefficient of 
determination for each metabolite was greater than 0.99 and can be seen in Table 7.  In an 
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effort to determine whether the method maintained linearity at the three lowest 
concentrations, 30-100 ng/mL, R2 values were calculated by ChemStation.  
Table 7.  Coefficient of determination for the  
lowest three calibrators and the entire curve. 
Metabolite R
2 Lowest 
Concentrations R
2 Entire Curve 
JWH-250 0.998 0.999 
JWH-018 0.999 0.998 
JWH-122 0.995 0.999 
 
 
3.1.4 Derivatization of the Synthetic Cannabinoid Metabolites 
The sensitivity of the GC/MS analysis varied from day-to-day, sometimes 
significantly when the analytes were underivatized.  A solution to the sensitivity concerns 
in the analysis was to derivatize the metabolites using BSTFA with 1% TMCS.  Blocking 
the hydroxyl group of the metabolites with the derivatizing agent decreased the polar 
interactions with the stationary phase, which decreased the compounds from interacting 
with the column (43).  However, the primary advantage to derivatization is the increased 
volatility and reproducibility of the flash vaporization process during injection of the 
samples into the GC.  This resulted in a significant increase in peak area of the 
metabolites, allowing for less of the standards to be spiked into the urine for analysis.  
Derivatization also helped to increase the thermal stability of the metabolites.  Due to the 
stability and volatility of the derivatized analytes, a more consistent concentration of the 
metabolites was injected into the column, resulting in more reproducible chromatograms.   
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The GC/MS method was optimized again for the new derivatized compounds, 
which focused on oven temperature program, injection port temperature, and transfer line 
temperature.  Since the mass of the compounds was increased by 72 amu from the loss of 
a hydrogen and an addition of the trimethylsilyl group (Si(CH3)3), a new SIM method was 
created to account for the differences in mass.  A comparison of a 50 μg/mL metabolite 
mixture versus a derivatized sample of the same concentration can be seen in Figure 11. 
 
Figure 11: Chromatograms of the metabolites derivatized versus underivatized.  
Derivatization increased the peak area of the metabolites and decreased the baseline. 
 
Even after all of the considerations and changes to the method, variations in the 
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collected and analyzed.  The high concentration was analyzed once per every set of 
samples and was used to compare the results of these experiments with ones conducted 
previously when a higher concentration was necessary.  A separate liner was used for 
analysis of these compounds; however, it became dirty after a number of samples had 
been injected.  The derivatizing agent caused the liner to become dirtier faster than it had 
previously.  To prevent this from affecting the data, the liner was switched more often.  
With the increased sensitivity from derivatization, fronting of the peaks was observed, 
indicating the column was overloaded with the compounds. 
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Figure 12: Chromatograms of the interday variation of the derivatized metabolites.  
Between weeks 1 and 2, a new liner was used.  While this showed an increase in 
abundance of the peaks, the ratios between the metabolites were still similar.  The other 
two samples were also analyzed a week apart; however, they overlapped very well.  It 
indicated that if a clean liner was used with derivatization, the reproducibility increased 
significantly.   
 
 While some interday variability persisted, samples analyzed on the same day had 
comparable results.  A new calibration curve was created including the derivatization 
step.  The seven calibration standards were spiked with 5 ng/mL to 10 μg/mL of the 
0.E+00%
5.E+06%
1.E+07%
2.E+07%
2.E+07%
3.E+07%
3.E+07%
4.E+07%
4.E+07%
5.E+07%
13% 13.5% 14% 14.5% 15% 15.5% 16% 16.5%
Ab
un
da
nc
e!
Retention Time (min)!
Week 1!
Week 2!
Week 3!
JWH-250!
JWH-122!
!
JWH-018!
37 
metabolites and 300 ng/mL of the internal standards.  The coefficient of determination for 
each metabolite was greater than 0.99 and can be seen in Table 8. 
Table 8.  Coefficient of determination for the lowest three  
calibrators and the entire curve of the derivatized metabolites. 
Metabolite R
2 Lowest 
Concentrations R
2 Entire Curve 
JWH-250 0.999 0.999 
JWH-018 0.997 0.999 
JWH-122 0.997 0.999 
 
 
3.2 SPE Procedure Utilized in this Study 
3.2.1 Metabolites Interaction with the SPE Cartridges 
 In the SPE procedure, urine was diluted with a pH 6 phosphate buffer to 
normalize the samples.  Since an individual’s urine can have different pH values, adding 
the buffer regulates the starting pH for all samples.  This also kept the metabolites in a 
neutral state, thus the only interactions were between the nonpolar portions of the 
cartridges and metabolites.  A lower pH would cause the tertiary amine to be protonated 
and a higher pH would cause the hydroxyl to be deprotonated.  Elution by gravity was 
used for all of the cartridges.  This is the slowest form of elution, which allows for the 
most efficient extraction of the analytes.   
The conditioning of the cartridge removed impurities remaining from the 
manufacturing process and evenly packed the sorbent, while the buffer prepared the 
cartridge for the buffered urine sample.  After the sample was applied, the cartridge was 
washed with deionized water to remove the aqueous impurities.  The 80:20 buffer and 
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acetonitrile solution removed the other unwanted components of the urine, including the 
neutral biologicals, polar compounds, and residual organics.  The cartridge was dried 
under a vacuum in order to remove all remaining aqueous solvents because they interfere 
with derivatization and are difficult to evaporate.  After the collection vial was changed, 
the ethyl acetate and methanol solution eluted the metabolites from the cartridge.   
 
3.2.2 Observations Throughout the SPE Procedure 
During the SPE procedure, differences between the brands were observed.  
SiliCycle had the most consistent flow rate between the cartridges analyzed in triplicate.  
Within one minute, each of the cartridges were finished eluting the solvents.  The 
procedure from the beginning to the drying step was completed within 22 minutes.  
Agilent had the most inconsistent flow rate between triplicate samples and could take up 
to 55 minutes to reach the drying step in the procedure.  The results of analyte recovery 
between the brands also differed.  The UCT and SiliCycle cartridges produced results 
every time the procedure was conducted; however, Thermo and Agilent had several 
cartridges that gave no results after spiking the urine and conducting the analysis.  Table 
9 shows the observations made during comparison of the four brands throughout the SPE 
procedure.  
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Table 9.  Observations made throughout the SPE procedure. 
Brand Elution Rate (min) 
Time to 
Drying Step 
(min) 
Percentage of 
Cartridges with 
No Results 
SiliCycle <1 22 0 
UCT 3-5 40 0 
Thermo <1 20 10.5% 
Agilent 10-15; (27)* 55 13% 
Note: The second column reports time values for the range of triplicate elution rates.  The 
consistent elution rates for the triplicate samples demonstrate reproducibility of the cartridges. 
*One sample was 27 minutes behind the rest of the Agilent cartridges prepared at the same time. 
 
 
3.2.3 Calibration Curves for the Brands of Cartridges after Extraction of the Metabolites 
Calibration standards that were spiked into urine were made in concentrations 
between 50 and 2000 ng/mL for each of the cartridges.  The linearity for each of the 
brands of cartridges was different.  In this study, data points for the UCT and Thermo 
brands of cartridges were discarded, which allowed for a focused study over the range in 
which the cartridges were effective.  An example calibration curve for SiliCycle is shown 
in Figure 13. 
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Figure 13: Calibration curves for SiliCycle cartridges.  The insets to each curve show 
the linearity for the three lowest calibrators.  The x- and y-axes were calculated by a 
comparison of the metabolites to the internal standards. 
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Thermo cartridges had poor linearity at the lower points of the calibration curve; 
therefore, the lowest data point was discarded.  This resulted in an adjusted range of 100-
2000 ng/mL, which can be seen in Table 10.  While the R2 values over the entire range 
was above 0.99, the values at the lowest three calibration points were between 0.96 and 
0.99, even after removing the lowest calibration point.  This could be due to the 
stationary phase of the cartridge adsorbing the analytes too strongly or not at all.  It could 
also be from human errors in pipetting and in the SPE procedure. 
 UCT had poor linearity at the higher points of the calibration curve, which 
appeared to plateau.  The highest data point was discarded, resulting in an adjusted range 
of 50-1000 ng/mL.  This could be due to a saturation of the cartridge at the higher 
concentrations or from human errors in pipetting and in the SPE procedure. 
Agilent and SiliCycle had good linearity throughout the entire concentration range 
of 50-2000 ng/mL.  The linearity for Agilent decreased from JWH-018 to -122 and -250 
metabolites, while SiliCycle decreased from JWH-250 to -018 and -122 metabolites.  
This illustrates the different interactions between the metabolites and the cartridges.  The 
increased linearity could be due to the manufacturing of the cartridges, or from human or 
instrumental errors throughout the procedure.   
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Table 10.  Coefficient of determination for the 
brands and metabolites over an adjusted range. 
Brand Metabolite R
2 Lowest 
Concentrations 
R2 Entire 
Curve 
Thermo 
(100-2000 ng/mL)* 
250 0.968 0.996 
018 0.974 0.992 
122 0.993 0.996 
UCT 
(50-1000 ng/mL)* 
250 0.999 0.995 
018 0.999 0.997 
122 0.999 0.995 
SiliCycle 
(50-2000 ng/mL) 
250 0.999 0.998 
018 0.999 0.996 
122 0.998 0.995 
Agilent 
(50-2000 ng/mL) 
250 0.998 0.993 
018 0.999 0.999 
122 0.999 0.999 
*Thermo and UCT cartridges required a set of data points to be discarded. 
 
3.2.4 Recovery Efficiency Study for the Extraction of the Metabolites 
 The recovery efficiency of a cartridge measures the approximate amount of 
analyte that the cartridge extracts from the matrix.  A general recovery efficiency of the 
metabolites is an important comparison between the cartridge brands.  In this experiment, 
the synthetic urine samples were spiked with 1000 ng/mL of each metabolite and 300 
ng/mL of each internal standard.  The extracted, derivatized samples were compared to 
un-extracted, derivatized samples spiked in methanol in order to calculate the recovery 
efficiency of the quantification ion.  
Figure 14 shows the percent recovery for each metabolite and each brand.  
SWGTOX has a tolerance of ±20% of the actual value, so values between 80-120% are 
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acceptable (47).  Following these guidelines, SiliCycle has the best percent recovery with 
the triplicate samples and their standard deviations falling within ±20% of 100%.  While 
the averages of the percent recoveries for Thermo and UCT are in the acceptable range, 
the error bars are outside of the range, which show the variation between the triplicate 
samples.  Agilent had a lower recovery for JWH-250 and -122 metabolites that did not 
fall within the acceptable range.  However, the JWH-018 metabolite had one replicate at 
139%, which increased the standard deviation.   
Figure 14:  Recovery efficiency percentage of the SPE cartridges for each 
metabolite.  The percent recovery is the average of the triplicate samples and the error 
bars show the standard deviation for the replicates.  SiliCycle has the closest percent 
recovery to 100%, followed by Thermo, UCT, and Agilent. 
 
A cartridge that has a lower recovery efficiency than 100%, like JWH-250 and -
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analyte as efficiently as it should.  The metabolites could be eluting during the washing 
step of the procedure.  This could also suggest that the sorbent interacts too strongly with 
the metabolites, with the elution solvent not removing the metabolites from the sorbent.  
A cartridge that has a recovery efficiency higher than 100%, like the Thermo cartridges, 
could indicate that other components of the urine adsorb to the sorbent and are then 
eluted with the metabolites, interfering with the quantitation of the analytes.  These 
differences could also be from human error during the spiking of the samples or from the 
SPE procedure. 
 
3.2.5 Within-Run Precision Study for Synthetic Cannabinoid Metabolites 
The reproducibility of SPE cartridges is very important in a laboratory where half 
of all samples must be retained when additional testing could be required, or with small 
samples when the entire sample cannot be consumed.  The within-run precision study 
measures the coefficient of variation to determine the reproducibility of the procedure.  In 
this experiment, the urine samples were spiked with 1000, 500, and 250 ng/mL of the 
metabolites and 300 ng/mL of the internal standards.  The calculation from the SWGTOX 
validation guidelines was used to compare the results from each brand of SPE cartridges. 
A higher % CV represented more variation between replicates while a lower value 
indicated reproducibility.  The differences in the % CV for the brands were visible with 
SiliCycle having the least amount of variation across all three metabolites and Agilent 
having the most variation.  The graphs seen in Figure 15 were created by dividing the 
standard deviation by the mean for each set of triplicate samples.   
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Figure 15: Precision study graphs for each brand of SPE cartridges.  The blue 
columns represent the JWH-250 metabolite, red is JWH-018 metabolite, and green is 
JWH-122 metabolite.    
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The SWGTOX acceptable coefficient of variation is <20% (47).  According to 
that requirement, all of the brands fall within the appropriate limits for the within-run 
precision study.  SiliCycle had the best reproducibility because it exhibited the least 
amount of variation between triplicate samples, followed by UCT, Thermo, and Agilent 
with the most variation.  
Comparison of the observations from section 3.2.2 with the calculated coefficient 
of variation for each of the samples matched up as well.  The consistency of flow rates 
for UCT and SiliCycle could contribute to the lower variation between triplicate samples.  
The higher variation seen in Agilent could be due to the inconsistent flow rates observed 
during the SPE procedure and in the percentage of cartridges that gave no results, which 
required some samples to be retested.  Thermo’s increased variability for the lower 
concentrations could be explained from its calibration curve, where the lower 
concentrations had the poorest coefficient of determination.  While the observations and 
comparisons of the data are in agreement, more samples must be tested to contribute to 
these conclusions.  Since this experiment was only conducted once, it does not account 
for the influences from human errors or instrumental variations.   
 
3.3 GC/MS vs. LC/MS for the Analysis of Synthetic Cannabinoid Metabolites 
Some of the issues faced during the GC method development could have been 
avoided by using LC/MS for instrumental analysis.  While GC has more theoretical plates 
for better resolution, LC is a better method of analysis for toxicological samples because 
volatility, thermal stability, and polarity are not limitations of LC based separations in 
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comparison to GC (35, 48, 49).  In LC, the compounds could be separated based on 
interactions with the stationary phase of the column as well as a gradient elution rather 
than the very high temperatures needed to elute the metabolites from the GC column.  
These temperatures caused a tremendous amount of column degradation, which was 
observed in the chromatograms as the numerous and abundant siloxane peaks as well as 
the high baseline.  This continuous column bleed made it difficult in choosing unique 
ions for the SIM method to detect the metabolites.   
The condition of the liner was also an important issue to consider.  As more 
samples were injected, the liner became dirtier, resulting in chromatograms with less 
abundant peaks from samples that were spiked with the same concentration of standards.  
While derivatization helped to increase the abundances of the peaks, it also appeared to 
cause the liner to become dirtier, faster.  After approximately 90 samples, including 
blanks, the liner generated a dark area at the depth the samples were injected.  Since this 
was not visible until the end of sample collection, it affected the quantitation of samples 
that were analyzed on different days than the calibration curves.  This indicated a long 
sequence with many samples should not be run at once due to potential interactions 
between the metabolites and impurities in the liner. 
Using an LC instrument would save the analyst time and the multiple issues 
associated with interday variations seen in these experiments.  LC has improved 
tremendously over the past few years and has become a robust and reliable technique in 
toxicological analysis (49).  There is no need to derivatize the compounds, making the 
sample preparation less extensive and less expensive than GC (35).  Since there is not a 
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liner involved with the LC instrumentation, the degradation seen in this study caused by 
the liner would be eliminated as well.  While GC has a better separating power, LC is a 
more appropriate analytical method for metabolites (48).  However, the experiments 
conducted in this research demonstrate that GC can be utilized to analyze synthetic 
cannabinoid metabolites if necessary. 
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4. CONCLUSIONS 
The outcome of these experiments led to the development of a GC/MS method for 
detection of three JWH metabolites, creation of calibration curves for quantification, use 
of SPE for the extraction of the metabolites from urine, and the quantification of the 
extracted compounds to determine the efficacy and reproducibility of four brands of SPE 
cartridges.  Method optimization was able to minimize the interday variations seen in the 
same samples.  Optimized parameters include: initial validation of the GC/MS method in 
each lab, a clean liner for the analysis of synthetic cannabinoid metabolites, use of a GC 
column with a high temperature limit, and derivatization of the extracts before injection 
into the GC.   
The differences between the types of samples analyzed by a GC can affect the 
performance of the instrument for these compounds.  To produce the best results, the 
parameters of the GC/MS method must be validated for synthetic cannabinoid 
metabolites on each instrument utilized.  A clean liner must be used and watched closely 
as the analysis of numerous samples can significantly affect the results of the metabolites.  
Derivatization must occur in order for the volatility and thermal stability of the 
metabolites to increase, which heightened the sensitivity for detection of the analytes.  A 
high temperature column must be used, due to the intense temperatures needed for elution 
of these compounds.  This reduces the amount of column degradation and can help to 
decrease the baseline caused by the elution of siloxanes.  Due to the variation of interday 
analysis, calibration curves must be run at the same time as the samples.  Analyzing them 
at a similar time allows for a more accurate quantification of the metabolites. 
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A compilation of the observations throughout the SPE procedure and results of 
the cartridges can be seen in Table 11.  SiliCycle cartridges had the most reliable percent 
recovery, the best reproducibility, and the most consistent and fastest elution rate.  UCT 
had similar results to SiliCycle, except for a larger standard deviation in the recovery 
efficiency study.  Thermo had a higher coefficient of variation at the lower 
concentrations, seen in the within-run precision study.  With the standard deviations 
taken into account, UCT and Thermo were not within the ±20% accepted by the 
SWGTOX guidelines for the recovery efficiency study.  The Agilent cartridges had the 
most inconsistent and slowest flow rate.  They also had the highest variation between 
replicates and were not within the accepted tolerance in the recovery efficiency study.  
However, under the SWGTOX guidelines of <20% for the coefficient of variation 
percentage, all of the brands were within the acceptable range.   
Table 11.  Overall comparison of cartridges throughout these experiments. 
 SiliCycle UCT Thermo Agilent 
Elution Flow Rate Fast, consistent 
Slow, 
consistent 
Fast, 
consistent 
Very slow, 
inconsistent 
Within 
±20% 
Percent 
Recovery 
Mean Yes Yes Yes No 
Standard 
Deviation Yes No No No 
Reproducibility, 
Highest to Lowest 1 2 3 4 
<20% CV Yes Yes Yes Yes 
 
The apparent interaction that the metabolites have with impurities in the GC liner 
may cause degradation peaks in the chromatograms.  With this knowledge, measures can 
be taken to lessen the effects of degradation in a laboratory setting.  Derivatization is 
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usually recommended when analyzing metabolites; however, there are articles that state if 
a peak is observed to a certain degree, derivatization is not necessary for reliable 
detection, but may be utilized for considerations related to sensitivity (38).  The 
manufacturer of the metabolites purchased for these experiments stated they did not 
derivatize the compounds because they could detect them.  Based on the significant 
increase in instrument performance and reproducibility observed in these experiments, 
derivatization should be done when analyzing these metabolites.  This research 
demonstrates that with constant changes and developments to the instrument and 
methods, GC/MS can be utilized for this analysis.  With the combination of a clean liner 
and derivatization of the metabolites, reproducible chromatograms can be produced.   
From the conclusions drawn from these experiments, LC/MS should be utilized 
instead of GC/MS for the analysis of synthetic cannabinoid metabolites, especially in a 
laboratory where the instrument gets a lot of varied use.  While this study shows it is 
possible to use GC/MS for the analysis of these metabolites, theoretically, LC/MS should 
be more reproducible.  The use of GC/MS for the analysis of synthetic cannabinoid 
metabolites can be done, but if available, LC/MS may be the more appropriate option.   
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5. FUTURE DIRECTIONS 
Future directions of this research would be to conduct the precision study over the 
course of several days.  The method used should be validated over the parameters in the 
SWGTOX validation document.  Optimization of the GC/MS parameters to determine 
the limit of detection (LOD) and limit of quantitation (LOQ) for the method as well as the 
four brands of cartridges should be completed.  This research would be beneficial for real 
life applications in the laboratory, as limited samples may be exhausted.  Then, the 
extraction efficiencies of each of the brands could be tested and compared over multiple 
days with high, medium, and low concentrations. The experiment involving the cartridge 
comparison could be repeated using LC-MS/MS to test the LOD and LOQ for the 
cartridges in the same manner and to compare the analysis to the GC/MS results. 
This experiment used synthetic urine spiked with the metabolites of interest, but 
in actual urine samples, the metabolites will be conjugated with glucuronic acid and must 
undergo hydrolysis before SPE (37).  Further studies would need to be done on the 
hydrolysis of the metabolites and subsequent SPE procedure of the hydrolyzed 
metabolites to determine if that would affect the efficacy or reproducibility of the 
cartridges.  
The rapid turnover for the abuse of the compounds indicates the applicability of 
these specific GC/MS and SPE methods may not be relevant when the JWH-018, -250, 
and -122 compounds are no longer used.  The methods optimized in this project may 
work for other compounds, but they are a starting point for future research of new 
synthetic compounds.  It is imperative that future experiments be conducted utilizing 
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more metabolites tested of different types of synthetic cannabinoids to determine whether 
different brands are more useful for certain categories of compounds.   
The SPE procedure could be further optimized.  The cartridges used in this 
experiment were mixed mode, reversed phase with anion exchange sites.  Since the 
metabolites were kept in a neutral state, the anion exchange sites were not utilized.  After 
determining the pKa of the metabolites, many experiments could be done by changing the 
pH of the buffer and ionizing the metabolites to interact with the anion exchange sites.  
The same experiment could be conducted on nonpolar cartridges as well.  The eluent 
used to elute the analytes from the sorbent could be tested to determine whether a more 
nonpolar solution would affect the reproducibility or efficiency of the cartridges.  Lower 
volumes of the eluent could also be assessed to decrease the amount of solvents utilized 
and the evaporation time of the TurboVap.  Overall, this area of study has become more 
popular over the past decade and more research needs to be done to provide toxicology 
labs with the best methods of analysis for these compounds. 
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